跳到正文
原文
MedPage Today·· 3 天前AI 评分50

过去30年肥胖相关癌症死亡率翻倍

Obesity-Related Cancer Deaths Doubled Over the Past 30 Years

AI 导读

美国数据显示,1990年至2023年,肥胖相关癌症死亡率翻倍,其中肝癌、胰腺癌和子宫癌死亡率增长最快。这表明肥胖与癌症之间的关联正在加剧,需要加强预防和治疗措施。

正文

— Liver, pancreatic, and uterine cancer deaths drove the surge

November 17, 2026 • 3 min read

NATIONAL HARBOR, Md. -- Deaths attributable to cancers related to high body mass index (BMI) have more than doubled over the past three decades, according to U.S. data.

Using estimates from the Global Burden of Disease 2023 study, cancer deaths linked to a BMI of 25 or higher increased 104.2%, from 23,236 in 1990 to 47,450 in 2023, reported Digantkumar Patel, MD, of the Springfield Clinic in Illinois.

During this period, the age-standardized death rate increased by 8.1%, from 7.28 to 7.87 per 100,000 people. That uptick indicates that the rise in obesity-related cancer deaths "cannot be explained by population growth and aging alone," Patel said at the ObesityWeek annual meeting.

"We all know about the association between obesity and cancer, but we have less information about how much the burden of these cancers has changed over time," he noted, suggesting that pinpointing the fastest-growing malignancies can help target screening and prevention.

"Our findings reinforce the importance of obesity prevention and treatment as a part of cancer prevention," Patel added.

Among the 12 high BMI-related cancers, deaths from liver, pancreatic, and uterine cancers grew the fastest between 1990 and 2023, with increases of 566% (from 913 to 6,081 deaths), 487% (from 414 to 2,432 deaths), and 193% (from 1,935 to 5,677 deaths).

Despite those sharp increases, colorectal cancer accounted for the highest total number of high BMI-related cancer deaths in 2023, at 11,161, reflecting a 53% increase in deaths since 1990.

Total deaths also rose for the remaining eight cancers -- thyroid (+145%), multiple myeloma (+121%), kidney (+104%), leukemia (+73%), ovarian (+69%), gallbladder/biliary tract (+61%), non-Hodgkin lymphoma (+60%), and breast (+50%) -- though age-standardized mortality rates actually declined over time by average annual percent change for breast (-0.91%), non-Hodgkin lymphoma (-0.82%), colorectal (-0.57%), ovarian (-0.33%), gallbladder/biliary tract (-0.26%), and leukemia (-0.17%).

These shifts rearranged the mortality rankings among high BMI-related cancers during this time period. Liver cancer jumped from eighth to second place, uterine cancer climbed from fifth to third, and pancreatic cancer moved from 11th to seventh. Meanwhile, breast cancer dropped from second to fourth place, kidney cancer fell from third to fifth, and leukemia dipped from fourth to sixth. Thyroid cancer remained in 12th place throughout the study period.

Disability burden climbed alongside mortality. Since 1990, disability-adjusted life years (DALYs) nearly doubled, rising 97.4% from 560,000 to 1.11 million, while years lived with disability spiked 129.5%, from 36,997 to 84,892.

Adults ages 55 to 79 bore the brunt of the burden, accounting for 71.3% of all high BMI-related cancer DALYs in 2023, with the heaviest concentration among those ages 65 to 69. In adults 70 and older, DALYs surged by 615% for liver cancer and 655% for pancreatic cancer.

However, among females ages 15 to 39, uterine cancer DALYs rose 220%. "This is particularly concerning because it suggests that the growing burden is not limited only to older adults," Patel said.

The burden also varied by geography. Age-standardized death rates increased in 37 states, led by those in the South. West Virginia, Kentucky, and Mississippi recorded the highest death rates in 2023, while the steepest increases since 1990 occurred in Oklahoma (+43%), West Virginia (+39%), New Mexico (+36%), and Tennessee (+36%). Conversely, the largest declines were seen in Washington, D.C. (-26%), New Jersey (-18%), and New York (-17%).

After colorectal cancer, uterine or liver cancer ranked second for high BMI-related cancer deaths in nearly every state, except in Mississippi and Alabama, where breast cancer held the second spot.

"It suggests that cancer prevention strategies should be catered to different regions rather than using the same approach in all states," Patel said. "From a public health perspective, we need to focus resources in states where the burden is highest and the fastest-rising."

Moving forward, he noted that research should examine disparities by sex and race and model projections through 2060 to account for the expanding use of modern obesity treatments, including GLP-1 medications.

来源:MedPage Today · medpagetoday.com